BACKGROUND: Providers treating chronic pain must attempt to relieve suffering, while minimizing problematic prescription opioid use, including addiction and diversion. Previously described risk factors for problematic use include history of substance use, younger age, male sex, psychiatric comorbidity, and lower education level. METHODS: We examined these risk factors in HIV-infected individuals, using cross-sectional and longitudinal data from the Manhattan HIV Brain Bank. Problematic use was defined as illicit substance use (documented by urine toxicology or structured psychiatric interview), while receiving prescription opioids. RESULTS: Among 173 participants prescribed opioids, 62% had problematic use, the majority of which was discovered by urine toxicology. Problematic use was associated with past substance use, current psychiatric disorder, and poorer adherence to antiretrovirals. However, when participants without problematic use at baseline were followed longitudinally, these factors were not predictive. Furthermore, the cumulative incidence of problematic use behaviors was no greater than in a similar group of participants who were not prescribed opioids. CONCLUSIONS: Problematic prescription opioid use is common among HIV-infected individuals and is associated with history of substance use, current psychiatric disorder, and poor adherence to antiretrovirals. However, these factors do not predict future problematic use in those who are not currently using illicit substances, and the prescription of an opioid does not seem to predispose patients toward a future substance use disorder. Rather than attempting to assess risk for problematic prescription opioid use in HIV-infected individuals, we recommend baseline and follow-up urine toxicology.
BACKGROUND: Providers treating chronic pain must attempt to relieve suffering, while minimizing problematic prescription opioid use, including addiction and diversion. Previously described risk factors for problematic use include history of substance use, younger age, male sex, psychiatric comorbidity, and lower education level. METHODS: We examined these risk factors in HIV-infected individuals, using cross-sectional and longitudinal data from the Manhattan HIV Brain Bank. Problematic use was defined as illicit substance use (documented by urine toxicology or structured psychiatric interview), while receiving prescription opioids. RESULTS: Among 173 participants prescribed opioids, 62% had problematic use, the majority of which was discovered by urine toxicology. Problematic use was associated with past substance use, current psychiatric disorder, and poorer adherence to antiretrovirals. However, when participants without problematic use at baseline were followed longitudinally, these factors were not predictive. Furthermore, the cumulative incidence of problematic use behaviors was no greater than in a similar group of participants who were not prescribed opioids. CONCLUSIONS: Problematic prescription opioid use is common among HIV-infected individuals and is associated with history of substance use, current psychiatric disorder, and poor adherence to antiretrovirals. However, these factors do not predict future problematic use in those who are not currently using illicit substances, and the prescription of an opioid does not seem to predispose patients toward a future substance use disorder. Rather than attempting to assess risk for problematic prescription opioid use in HIV-infected individuals, we recommend baseline and follow-up urine toxicology.
Authors: Beatrix M Schieffer; Quyhn Pham; Jennifer Labus; Ariel Baria; Walter Van Vort; Philip Davis; Frederick Davis; Bruce D Naliboff Journal: J Pain Date: 2005-09 Impact factor: 5.820
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Ajay D Wasan; Stephen F Butler; Simon H Budman; Christine Benoit; Kathrine Fernandez; Robert N Jamison Journal: Clin J Pain Date: 2007-05 Impact factor: 3.442
Authors: Timothy J Ives; Paul R Chelminski; Catherine A Hammett-Stabler; Robert M Malone; J Stephen Perhac; Nicholas M Potisek; Betsy Bryant Shilliday; Darren A DeWalt; Michael P Pignone Journal: BMC Health Serv Res Date: 2006-04-04 Impact factor: 2.655
Authors: Lisa R LaRowe; Lauren N Chilcott; Michael J Zvolensky; Peter A Vanable; Kelley Flood; Joseph W Ditre Journal: Subst Use Misuse Date: 2018-04-30 Impact factor: 2.164
Authors: Andrea H Weinberger; Elizabeth K Seng; Joseph W Ditre; Melody Willoughby; Jonathan Shuter Journal: Nicotine Tob Res Date: 2019-03-30 Impact factor: 4.244
Authors: Mary Catherine George; Arada Wongmek; Michelle Kaku; Alexandra Nmashie; Jessica Robinson-Papp Journal: Behav Med Date: 2015-12-11 Impact factor: 3.104
Authors: Sara D Pullen; Christi Acker; Haemi Kim; Morgan Mullins; Payton Sims; Holly Strasbaugh; Samantha Zimmerman; Carlos Del Rio; Vincent C Marconi Journal: AIDS Res Hum Retroviruses Date: 2020-06-02 Impact factor: 2.205